Savient sells its biologics

March 2005
Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p2
Trade Publication
Reports that Savient Pharmaceuticals Inc. has shed its global biologics manufacturing operations to two subsidiaries of Lausanne, Switzerland-based biopharmaceutical Ferring Holding SA. Amount that will be paid by Ferring; Global rights gained by Ferring to human growth hormone and other products.


Related Articles

  • Seeking a buyer as drug goes to market. Kaltwasser, Jared // njbiz;11/1/2010, Vol. 23 Issue 44, p3 

    The article reports on the plan of Savient Pharmaceuticals Inc. to move forward with the launch of its lead drug Krystexxa for the treatment of chronic gout in adults.

  • Ferring counsel departs due to Swiss role. Moshinsky, Ben // Lawyer;3/20/2006, Vol. 20 Issue 11, p8 

    The article reports on the departure of lawyer Patricia Barclay from Ferring Pharmaceutical Inc. after the firm relocated from Copenhagen to Wallisellen, Switzerland. Barclay is determined not to move with the company headquarters, which could result Ferring without a general counsel for much of...

  • Savient Shares Tumble on Extension Safety Data.  // Bioworld Week;11/3/2008, Vol. 16 Issue 44, p3 

    The article reports on the decrease in the shares of Savient Pharmaceuticals Inc. following the company's presentation of data on its pegloticase (Puricase) for treatment-resistant gout in the U.S. Analysts' main concerns are the safety issue of the drug and the size of its market. The company...

  • Pharma & Fine Chemicals: Market Briefs.  // Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p12 

    Presents news briefs from the pharmaceuticals and fine chemicals industries as of September 20, 1999. Acquisition of marketing and distribution rights for Sanofi-Sythelabo's Dynabac in the United States by Muro Pharmaceutical Inc.; Marketing approval received by Nordisk AS for its liquid growth...

  • Parallel Trader Plays Hardball. Gopal, Kevin // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p21 

    Focuses on the lawsuit filed by German pharmaceutical company Ferring against parallel-trader Erim-Pharm (E-P). Information on Ferring's voluntary withdrawal of marketing authorization for its desmopressin spray, Minirin; Comments from observers on the intention of Ferring to prevent parallel...

  • UBS Pharma Forum Yields M&A Sound Bites. Cohen, Judy Radler // Mergers & Acquisitions Report;5/1/2006, Vol. 19 Issue 17, p3 

    Reports on speculations regarding the possible spinoff of Rosemont Pharmaceuticals by Savient Pharmaceuticals Inc. Market capitalization review of Rosemont conducted by Savient according to remarks by CEO Christopher Clement at the 2006 UBS Global Specialty Pharmaceuticals Conference in New...

  • FDA Gout Route Unimpeded, but Will Docs Jump Aboard? Osborne, Randy // BioWorld Insight;3/29/2010, Vol. 18 Issue 13, p2 

    The article offers updates on various pharmaceutical companies including Savient Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and BioCryst Pharmaceuticals Inc. New Jersey-based Savient resubmits its biologics license application for Krystexxa in refractory patients. Takeda in Japan...

  • Watch Out For A Dangerous One-Two Punch.  // RN;Dec2004, Vol. 67 Issue 12, p72 

    Reports on Savient Pharmaceuticals Inc.'s issuance of a safety alert to nurses and other healthcare professionals regarding a possibly serious interaction between its anabolic steroid oxandroline (Oxandrin) and warfarin (Coumadin). Use of oxadrolone to promote weight gain; Evidence that...

  • Pipeline.  // Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p10 

    The article offers news briefs related to pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) submitted by Barr Laboratories Inc. to market the generic version of Dostinex. Ferring Pharmaceuticals announces the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics